Back grey_arrow_rt.gif
Fuzeon Sales
  DURHAM, N.C. - Sales of the HIV drug Fuzeon developed byTrimeris (Nasdaq: TRMS) are growing again, but the increase is slight and new statistics show revenues are not even half they were two years ago.
The drug, which is expensive and difficult to take due to required injections, recorded third quarter sales of $29.8 million, Trimeris said Wednesday. That total is $700,000 more than in the second quarter of $29.1 million. An increase of $1.3 million in the second quarter was the first growth in three quarters. However, the third quarter total is not even half of sales for the same time period in 2007 of $73.9 million. In 2008's third quarter, sakes were $45.5 million.
U.S. and Canada sales increased to $10.4 million in the quarter, up from $9.7 million. Global sales remained flat at $19.4 million.
Trimeris agreed two weeks ago to be acquired by Arigene, a South Korean company, for $81 million.
Fuzeon is manufactured, marketed and sold globally by Roche, Trimeris' partner.
  icon paper stack View Older Articles   Back to Top